



FORM PTO - 1449

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

ATTORNEY DOCKET NO.: MEE-002

APPLICANTS: Miller *et al.*

SERIAL NO.: 09/780,142

FILING DATE: February 9, 2001

EXAMINER: Huynh, P. GROUP: 1644

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
PNT	A9	2002/0049247	4/25/2002	Chen			
	A10	2003/0171320	9/11/2003	Guyer <i>et al.</i>			
	A11	2004/0167091	8/26/2004	Guyer <i>et al.</i>			
	A12	2005/0043220	2/24/2005	Guyer <i>et al.</i>			
✓	A13	6,270,749	8/7/2001	Blumenkranz <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
PNT	B8	WO 97/05127	2/13/1997						
	B9	WO 00/40089	7/13/2000						
	B10	WO 01/58240	8/16/2001						
✓	B11	WO 03/039404	5/15/2003						

## OTHER ART, JOURNAL ARTICLES, ETC.


EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
PNT	C119	"A Clinical Trial to Evaluate the Effect of an Experimental Compound on Reducing the Number of Retreatments Required in Photodynamic Therapy (PDT) with Visudyne™," Alcon web site, <a href="http://www.alconlabs.com/us/co/c-00-07study.ihtml">http://www.alconlabs.com/us/co/c-00-07study.ihtml</a> (printed April 4, 2003).							
	C120	Adamis, "Looking Forward: Ocular Biochemical Warfare - The VEGF Attack," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).							
	C121	Behling <i>et al.</i> , "Adeno-associated Delivery of TIMP-3 Inhibits Experimental Choroidal Neovascularization," <i>Invest. Ophthalmol Vis Sci</i> , 44: E-Abstract 1425 (2003).							
	C122	Blumenkranz <i>et al.</i> , "Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5," <i>Arch Ophthalmol</i> , 120(10):1307-14 (Oct. 2002).							
	C123	Bressler, "Photodynamic Therapy for AMD: Re-treatment Considerations," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).							
	C124	Campochiaro <i>et al.</i> , "The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration," <i>Molecular Vision</i> 5: 34-8 (Nov. 3, 1999).							
	C125	Ciulla <i>et al.</i> , "Age-Related Macular Degeneration: A Review of Experimental Treatments," <i>Surv. Ophthalmol</i> , 43(2): 134-46 (1998).							
✓	C126	Corjay <i>et al.</i> , "alpha,beta, alpha,Beta, and Osteopontin Immunostaining in Experimental Choroidal Neovascularization in the Monkey," Presentation #4473, Abstract on pg. S965.							

EXAMINER

DATE CONSIDERED

5/2/05

BEST AVAILABLE COPY



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
US 09/780,142

Sheet 2 of 4

FORM PTO - 1449

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

ATTORNEY DOCKET NO.: MEE-002

APPLICANTS: Miller *et al.*

SERIAL NO.: 09/780,142

FILING DATE: February 9, 2001

EXAMINER: Huynh, P. GROUP: 1644

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
PJK	C127	Csaky, K., "Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls (Comment)," <u>Ophthalmology</u> 110(5):879-81 (May 2003).
	C128	Dahlin <i>et al.</i> , "Design of a Specialized Cannula for Poserior Juxtapapillary Delivery of Anecortave Acetate to the Retina for Treatment CNV Associated with Age-Related Macular Degeneration," <u>Invest. Ophthalmol Vis Sci.</u> 44: E-Abstract 5036 (2003).
	C129	Danis, "Pharmacotherapy for AMD: The Role of Intravitreal Steroids and Related Agents," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).
	C130	de Juan, "Surgery for AMD: Limited Translocation in the Era of Photodynamic Therapy," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).
	C131	Eyetech Study Group, "Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results," <u>Ophthalmology</u> 110(5):979-86 (May 2003).
	C132	Gallemler <i>et al.</i> , "AMD Treatment Update: Along with Visudyne and TTT, injectable anti-angiogenesis agents are on the forefront of current research," <u>Ophthalmology Management</u> , 69-72 (March 2003).
	C133	Gauthier <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of rhuFab V2, an Anti-vascular Endothelial Growth Factor (VEGF) in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," ARVO Poster.
	C134	Gauthier <i>et al.</i> , "Safety and Efficacy of Intravitreal Injection of rhuFab VEGF in Combination With Verteporfin PDT on Experimental Choroidal Neovascularization," ARVO. The Association for Research in Vision and Ophthalmology (Oasis, Online Abstract Submission and Invention System, Program Planner, Presentation # 566).
	C135	Granville <i>et al.</i> , "Fas ligand and TRAIL augment the effect of photodynamic therapy on the induction of apoptosis in JURKAT cells," <u>International Immunopharmacology</u> 1: 1831-40 (2001).
	C136	Guyer, D.R., "Pharmacotherapy for AMD: VEGF Inhibitors and Related Agents," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).
	C137	Haimovici <i>et al.</i> , "Localization of Lipoprotein-delivered benzoporphyrin derivative in the rabbit eye," <u>Curr. Eye Res.</u> 16(2):83-90 (1997).
	C138	Heier <i>et al.</i> , "rhuFAB V2 (an Anti-VEGF Antibody Fragment) in Neovascular AMD: Safety and Tolerability of Multiple Intravitreal Injections - Preliminary Data from a Single Center," ARVO Poster.
	C139	Husain <i>et al.</i> , "Effects of Photodynamic Therapy Using Verteporfin on Experimental Choroidal Neovascularization and Normal Retina and Choroid up to 7 Weeks after Treatment," <u>Invest. Ophthalmol Vis Sci.</u> 40(10): 2322-31 (1999).
	C140	Husain <i>et al.</i> , "Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative," <u>Ophthalmology</u> 104(8):1242-50 (Aug. 1997).
	C141	International Search Report for PCT/US01/04231 completed on November 23, 2001
	C142	Kaiser <i>et al.</i> , "Five-Year Results of Verteporfin Therapy for Subfoveal CNV Due to AMD: Third Year of an Open-label Extension of the TAP Investigation," <u>Invest. Ophthalmol Vis Sci.</u> 44: E-Abstract 1099 (2003).
✓	C143	Kitchen <i>et al.</i> , "Anecortave Acetate Monotherapy for the Treatment of Occult and Minimally Classic Choroidal Neovascularization in Age-related Macular Degeneration," <u>Invest. Ophthalmol Vis Sci.</u> 44: E-Abstract 5039 (2003).
EXAMINER		DATE CONSIDERED

BEST AVAILABLE COPY

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

US 09/780,142

Sheet 3 of 4

PTO - 1449

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MEE-002

APPLICANTS: Miller *et al.*

SERIAL NO.: 09/780,142

FILING DATE: February 9, 2001

EXAMINER: Huynh, P. GROUP: 1644

## OTHER ART, JOURNAL ARTICLES, ETC.

EXAM.  
INIT.

## OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

Pak	C144	Kliman <i>et al.</i> , "Angiography and Photodynamic Therapy of Experimental Choroidal Neovascularization using Phthalocyanine Dye," <i>Invest. Ophthalmol. Vis. Sci. (Suppl.)</i> 30(3): 371 (1989).
	C145	Krzystolik <i>et al.</i> , "Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment," <i>Arch. Ophthalmol.</i> 120(2): 338-346 (2002).
	C146	Lai <i>et al.</i> , "Suppression of Choroidal Neovascularization by Adeno-associated Virus Vector Expressing Angiostatin," <i>Investigative Ophthalmology &amp; Visual Science</i> 42 (10): 2401-2407 (2001).
	C147	Leibowitz <i>et al.</i> , "The Framingham Eye Study Monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults," <i>Survey of Ophthalmology, Supplement</i> (May-June 1980).
	C148	Miller, "Photodynamic Therapy for AMD: Expanded Indications," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).
	C149	Ngo <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and Levinthal Paradox," Chapter 14 of <i>The Protein Folding and Tertiary Structure Prediction</i> , Merz and LeGrand, Eds., Burkhauser Boston, 1994.
	C150	Oleinick <i>et al.</i> , "The role of apoptosis in response to photodynamic therapy: what, where, why, and how," <i>Photochem. Photobiol. Sci.</i> 1: 1-21 (2002).
	C151	Olsen <i>et al.</i> , "An Evaluation of an Episcleral Anecortave Acetate Transscleral Drug Delivery System in Rhesus Monkey," <i>Invest. Ophthalmol Vis Sci.</i> 44: E-Abstract 4213 (2003).
	C152	Pasqualini <i>et al.</i> , "Organ Targeting in Vivo using Phage display Peptide Libraries," <i>Nature</i> 380: 364-6 (1996).
	C153	Reinke <i>et al.</i> , "Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey," <i>Ophthalmology</i> 106(10):1915-23 (Oct. 1999).
	C154	Renno <i>et al.</i> , "Expression of pigment epithelium-derived factor in experimental choroidal neovascularization," <i>Invest Ophthalmol Vis Sci.</i> 43(5):1574-80 (May 2002).
	C155	Renno <i>et al.</i> , "Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells," <i>Invest Ophthalmol Vis Sci.</i> 41(12):3963-71 (Nov 2000).
	C156	Renno <i>et al.</i> , "Photosensitizer delivery for photodynamic therapy of choroidal neovascularization." <i>Adv Drug Deliv Rev.</i> 52(1):63-78 (Oct. 31, 2001) Review.
	C157	Renno <i>et al.</i> , "Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2," <i>Arch Ophthalmol.</i> 122(7):1002-11 (July 2004).
	C158	Schlingemann <i>et al.</i> , "Role of vascular permeability factor/vascular endothelial growth factor in eye disease," <i>Br. J. Ophthalmol.</i> 81: 501-12 (1997)
	C159	Schmidt-Erfurth <i>et al.</i> , "Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study," <i>Arch Ophthalmol.</i> 117(9):1177-87 (Sept. 1999). Erratum in: <i>Arch Ophthalmol.</i> 118(4):488 (April 2000).
	C160	Sickenberg <i>et al.</i> , "A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes." <i>Arch Ophthalmol.</i> 118(3):327-36 (March 2000).
✓	C161	Slakter <i>et al.</i> , "Ancortave Acetate Administered as a Posterior Juxtapapillary Injection for Subfoveal CNV in Age-Related Macular Degeneration (AMD-Clinical Results)," Presentation at the Retina Congress 2002 Symposium (Sept. 8, 2002).

EXAMINER

DATE CONSIDERED


5/2/05

BEST AVAILABLE COPY

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

US 09/780,142

Sheet 4 of 4



RECEIVED PTO - 1449

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT

ATTORNEY DOCKET NO.: MEE-002

APPLICANTS: Miller *et al.*

SERIAL NO.: 09/780,142

FILING DATE: February 9, 2001

EXAMINER: Huynh, P. GROUP: 1644

## OTHER ART, JOURNAL ARTICLES, ETC.

EXAM.  
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

CP/it	C162	Slakter, "Pharmacotherapy for AMD: The Role of Periocular Steroids and Related Agents," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).
	C163	Slakter <i>et al.</i> , "Sub-Tenon's Administration of the Angiostatic Agent Anecortave Acetate in AMD Patients with Subfoveal Choroidal Neovascularization (CNV) - the Clinical Outcome," Invest. Ophthalmol Vis Sci. 44: E-Abstract 2909 (2002).
	C164	Slakter <i>et al.</i> , "Verteporfin With Altered (Delayed) Light in Occult CNV (VALIO) - Results of a Phase II Controlled Clinical Trial," Invest. Ophthalmol Vis Sci. 44: E-Abstract 1101 (2003).
	C165	Trese, "Treatment of Neovascularization in ROP: Pharmacological Agents and the ERTOP Study," American Academy of Ophthalmology Meeting (Retina, Giant Steps: A Look at the Past - An Eye on the Future) Subspecialty Day (The Wet Story: Exudative Age-Related Macular Degeneration) Presentation, Orlando, Fla. (Oct. 18-19, 2002).
	C166	Verma <i>et al.</i> , "Gene therapy - Promises, problems and prospects," Nature 389: 239-42 (Sept. 1997).
	C167	Yaacobi <i>et al.</i> , "In-Vivo Studies with Trans-Scleral Anecortave Acetate Delivery Device Designed to Treat Choroidal Neovascularization in AMD," Invest. Ophthalmol Vis Sci. 44: E-Abstract 4210 (2003).
	C168	Zacks <i>et al.</i> , "Caspase Activation in an Experimental Model of Retinal Detachment," <u>Investigative Ophthalmology &amp; Visual Science</u> 44(3): 1262-7 (March 2002).
✓	C169	Zacks <i>et al.</i> , "Verteporfin Photodynamic Therapy in the Rat Model of Choroidal Neovascularization: Angiographic and Histologic Characterization," <u>Investigative Ophthalmology &amp; Visual Science</u> 43 (0): 1-9 (2002).

EXAMINER

DATE CONSIDERED

5/2/05

BEST AVAILABLE COPY